A Phase 1 interventional study of QRL-101 Dose A and QRL-101 Dose B in Healthy, sponsored by QurAlis Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by QurAlis Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase I, prospective, single-center, randomized, double-blind, placebo-controlled, three-way cross-over study to evaluate the safety and tolerability of QRL-101 and investigate the pharmacodynamic effects of two dose levels of QRL-101 on transcranial magnetic stimulation (TMS) and nerve excitability threshold tracking (NETT) in healthy participants.
After screening and training, participants will be randomized to one of six treatment sequences of William's square balanced for first-order carry-over design consisting of two doses of QRL-101 or placebo, with at least seven days between each treatment.
QurAlis Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
*Other inclusion and exclusion criteria may apply*
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo
Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo
Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo
Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo
Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo
Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
Drug: QRL-101 Dose A · Drug: QRL-101 Dose B · Drug: Placebo
All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Single pulse TMS-EMG motor evoked potential (MEP) amplitude (μV) compared to placebo
To compare two dose levels of QRL-101 versus placebo on cortical excitability
Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.
mNETT strength-duration time constant (SDTC) compared to placebo SDTC
To compare two dose levels of QRL-101 versus placebo on peripheral motor nerve excitability
Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.
Other Single pulse TMS-EMG MEP parameters
To compare two dose levels of QRL-101 versus placebo on cortical excitability
Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.
pEEG: power in the alpha frequency bands in resting state with eyes open and closed
To compare two dose levels of QRL-101 versus placebo on spontaneous brain activity measured by resting state pharmaco-encephalography (pEEG)
Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.
Incidence of AEs and SAEs
Absolute values and changes from baseline values in vital signs, clinical laboratory tests, and ECG parameters
Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.
Plasma QRL-101 concentrations
AUC0-24
Time frame: 3 study periods, with a washout period of at least 7 days between each visit. Each study period consists of 2 nights and 1 study day.
Ran from Oct 2024 to primary completion in Dec 2024, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QRL-101
QurAlis Corporation